Stocks / NASDAQ / OKYO Pharma Limited

OKYO Pharma Limited

Our Opinion

OKYO Pharma Limited is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.

Supporting Evidence:

The company stated in the following press release that they use animals for drug testing.

“OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce positive results of OK-201, a non-opioid analgesic drug candidate, delivered topically in a mouse neuropathic corneal pain model demonstrating its potential to treat acute and chronic ocular pain.” Read the following article

Company Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Company Website: